Physician profile
Samya Ismail
NPI 1801498084
$3,228.49
in general payments reported to CMS, 2019-2025
21 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $27.15 · 2023: $1,173 · 2024: $765 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,201.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,065.63 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $423.92 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $392.57 | 2024-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $275.74 | 2023-2025 | Nucala, Trelegy Ellipta |
| Kaleo, INC. | $241.34 | 2023-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $232.42 | 2025 | Neffy |
| Optinose US, INC. | $161.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.86 | 2023-2025 | Fasenra, Tezspire |
| Amgen INC. | $35.58 | 2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $33.54 | 2025 | Takhzyro |
| Csl Behring | $29.41 | 2025 | Andembry |
| Pharming Healthcare, INC. | $28.12 | 2023 | Ruconest |
| Ucb, INC. | $27.15 | 2022 | |
| Paratek Pharmaceuticals, INC. | $26.18 | 2025 | Xhance |
| Genentech USA, INC. | $26.01 | 2023 | Xolair |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.00 | 2025 | |
| Grifols USA, LLC | $24.56 | 2024 | Xembify |
| Incyte Corporation | $20.47 | 2023 | Opzelura |
| Phadia US INC. | $20.00 | 2025 | Immunocap |
| Antares Pharma, INC. | $19.23 | 2024 | Xyosted |
| Ionis Pharmaceuticals, INC. | $18.06 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samya Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.